8-60852924-C-T
Variant summary
Our verdict is Pathogenic. The variant received 18 ACMG points: 18P and 0B. PVS1PM2PP5_Very_Strong
The NM_017780.4(CHD7):c.6199C>T(p.Gln2067*) variant causes a stop gained change involving the alteration of a conserved nucleotide. The variant was absent in control chromosomes in GnomAD project. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Pathogenic (★★). Synonymous variant affecting the same amino acid position (i.e. Q2067Q) has been classified as Likely benign. Variant results in nonsense mediated mRNA decay.
Frequency
Consequence
NM_017780.4 stop_gained
Scores
Clinical Significance
Conservation
Publications
- CHARGE syndromeInheritance: AD Classification: DEFINITIVE, STRONG, SUPPORTIVE Submitted by: Labcorp Genetics (formerly Invitae), Orphanet, PanelApp Australia, Broad Center for Mendelian Genomics, ClinGen, G2P
- hypogonadotropic hypogonadism 5 with or without anosmiaInheritance: AD Classification: STRONG Submitted by: Labcorp Genetics (formerly Invitae)
- hypogonadotropic hypogonadismInheritance: AD Classification: SUPPORTIVE Submitted by: Orphanet
- Kallmann syndromeInheritance: AD Classification: SUPPORTIVE Submitted by: Orphanet
- Omenn syndromeInheritance: AR Classification: SUPPORTIVE Submitted by: Orphanet
Genome browser will be placed here
ACMG classification
Our verdict: Pathogenic. The variant received 18 ACMG points.
Variant Effect in Transcripts
ACMG analysis was done for transcript: NM_017780.4. You can select a different transcript below to see updated ACMG assignments.
RefSeq Transcripts
| Selected | Gene | Transcript | Tags | HGVSc | HGVSp | Effect | Exon Rank | Protein | UniProt |
|---|---|---|---|---|---|---|---|---|---|
| CHD7 | NM_017780.4 | MANE Select | c.6199C>T | p.Gln2067* | stop_gained | Exon 31 of 38 | NP_060250.2 | ||
| CHD7 | NM_001316690.1 | c.1717-9305C>T | intron | N/A | NP_001303619.1 |
Ensembl Transcripts
| Selected | Gene | Transcript | Tags | HGVSc | HGVSp | Effect | Exon Rank | Protein | UniProt |
|---|---|---|---|---|---|---|---|---|---|
| CHD7 | ENST00000423902.7 | TSL:5 MANE Select | c.6199C>T | p.Gln2067* | stop_gained | Exon 31 of 38 | ENSP00000392028.1 | ||
| CHD7 | ENST00000524602.5 | TSL:1 | c.1717-9305C>T | intron | N/A | ENSP00000437061.1 | |||
| CHD7 | ENST00000695853.1 | n.6199C>T | non_coding_transcript_exon | Exon 31 of 37 | ENSP00000512218.1 |
Frequencies
GnomAD3 genomes Cov.: 32
GnomAD4 exome Cov.: 32
GnomAD4 genome Cov.: 32
ClinVar
Submissions by phenotype
CHARGE syndrome Pathogenic:5
This sequence change creates a premature translational stop signal (p.Gln2067*) in the CHD7 gene. It is expected to result in an absent or disrupted protein product. This variant is not present in population databases (ExAC no frequency). This variant has been observed in individuals affected with CHARGE syndrome (PMID: 23024289, Invitae). ClinVar contains an entry for this variant (Variation ID: 488803). Algorithms developed to predict the effect of sequence changes on RNA splicing suggest that this variant may create or strengthen a splice site, but this prediction has not been confirmed by published transcriptional studies. Loss-of-function variants in CHD7 are known to be pathogenic (PMID: 22461308, 25077900). For these reasons, this variant has been classified as Pathogenic.
The variant is not observed in the gnomAD v4.1.0 dataset. Predicted Consequence/Location: Stop-gained (nonsense): predicted to result in a loss or disruption of normal protein function through nonsense-mediated decay (NMD) or protein truncation. Multiple pathogenic variants are reported downstream of the variant. The variant has been reported at least twice as pathogenic with clinical assertions and evidence for the classification (ClinVar ID: VCV000488803 /PMID: 23024289). Therefore, this variant is classified as Pathogenic according to the recommendation of ACMG/AMP guideline.
not provided Pathogenic:1
The Q2067X variant in the CHD7 gene has been reported previously in a fetus with CHARGE syndrome (Legendre et al., 2012). This variant is predicted to cause loss of normal protein function either through protein truncation or nonsense-mediated mRNA decay. The Q2067X variant is not observed in large population cohorts (Lek et al., 2016). We interpret Q2067X as a pathogenic variant.
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at